China Golden Classic Group Limited (8281.HK)
HKD 0.11
(10.0%)
HKD 0.11
(10.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 30.31 Million CNY | 17.52% |
| 2022 | 27.67 Million CNY | -15.61% |
| 2021 | 32.53 Million CNY | -19.94% |
| 2020 | 42.9 Million CNY | 33.28% |
| 2019 | 31.96 Million CNY | 40.02% |
| 2018 | 21.65 Million CNY | 41.13% |
| 2017 | 16.78 Million CNY | -30.56% |
| 2016 | 22.49 Million CNY | -46.31% |
| 2015 | 41.09 Million CNY | 46.38% |
| 2014 | 28.12 Million CNY | 30.9% |
| 2013 | 21.44 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 656.5 Thousand CNY | 167.96% |
| 2024 Q2 | 656.5 Thousand CNY | 0.0% |
| 2023 Q3 | 7.8 Million CNY | 1593.49% |
| 2023 Q2 | 461 Thousand CNY | 219.43% |
| 2023 FY | - CNY | 17.52% |
| 2023 Q1 | -386 Thousand CNY | -103.71% |
| 2023 Q4 | 245 Thousand CNY | -96.86% |
| 2022 Q2 | 2.95 Million CNY | 169.88% |
| 2022 FY | - CNY | -15.61% |
| 2022 Q3 | 4.39 Million CNY | 48.85% |
| 2022 Q1 | -4.22 Million CNY | -143.47% |
| 2022 Q4 | 10.41 Million CNY | 136.8% |
| 2021 Q1 | -3.46 Million CNY | -121.96% |
| 2021 FY | - CNY | -19.94% |
| 2021 Q4 | 9.72 Million CNY | 56.8% |
| 2021 Q3 | 6.2 Million CNY | 103.88% |
| 2021 Q2 | 3.04 Million CNY | 187.92% |
| 2020 Q1 | -3.36 Million CNY | -155.33% |
| 2020 Q3 | 234 Thousand CNY | -98.16% |
| 2020 Q2 | 12.73 Million CNY | 478.34% |
| 2020 FY | - CNY | 33.28% |
| 2020 Q4 | 15.75 Million CNY | 6632.48% |
| 2019 Q3 | 8.21 Million CNY | 1039.94% |
| 2019 Q2 | 721 Thousand CNY | 263.49% |
| 2019 Q1 | -441 Thousand CNY | -302.29% |
| 2019 FY | - CNY | 40.02% |
| 2019 Q4 | 6.08 Million CNY | -25.99% |
| 2018 FY | - CNY | 41.13% |
| 2018 Q2 | -23 Thousand CNY | -100.69% |
| 2018 Q3 | 3.26 Million CNY | 14291.3% |
| 2018 Q1 | 3.33 Million CNY | -51.15% |
| 2018 Q4 | 218 Thousand CNY | -93.32% |
| 2017 Q3 | 8.91 Million CNY | 375.49% |
| 2017 Q2 | -3.23 Million CNY | 15.89% |
| 2017 Q1 | -3.84 Million CNY | -253.17% |
| 2017 FY | - CNY | -30.56% |
| 2017 Q4 | 6.82 Million CNY | -23.42% |
| 2016 FY | - CNY | -46.31% |
| 2016 Q4 | 2.51 Million CNY | -70.75% |
| 2016 Q3 | 8.58 Million CNY | 906.86% |
| 2016 Q1 | 6.3 Million CNY | -55.35% |
| 2016 Q2 | -1.06 Million CNY | -116.88% |
| 2015 FY | - CNY | 46.38% |
| 2015 Q4 | 14.11 Million CNY | 5.98% |
| 2015 Q2 | 2.61 Million CNY | 0.0% |
| 2015 Q3 | 13.31 Million CNY | 408.9% |
| 2014 FY | - CNY | 30.9% |
| 2013 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Natural Beauty Bio-Technology Limited | 22.91 Million HKD | -32.289% |
| Innovative Pharmaceutical Biotech Limited | 317.74 Million HKD | 90.461% |
| China Overseas Nuoxin International Holdings Limited | 2.02 Million HKD | -1393.839% |
| Prosperous Future Holdings Limited | -19.68 Million HKD | 253.967% |
| Huasheng International Holding Limited | 19.67 Million HKD | -54.03% |
| Fourace Industries Group Holdings Limited | 61.52 Million HKD | 50.735% |
| Evergreen Products Group Limited | 140.78 Million HKD | 78.47% |
| EC Healthcare | 737.83 Million HKD | 95.892% |
| Ming Fai International Holdings Limited | 211.83 Million HKD | 85.692% |
| Blue Moon Group Holdings Limited | 656.37 Million HKD | 95.382% |
| SuperRobotics Holdings Limited | -7.39 Million HKD | 509.65% |
| Takbo Group Holdings Limited | 25.8 Million HKD | -17.462% |
| Hyfusin Group Holdings Limited | 154.18 Million HKD | 80.342% |